Clemens C. Cyran1,2, Yanjun Fu2, Victor Rogut2, Bundit Chaopathomkul2, David M. Shames2, Michael F. Wendland2, Robert C. Brasch2
1Department of Clinical Radiology, University Hospitals Munich - Grosshadern, Munich, Germany; 2Radiology, University of California San Francisco, San Francisco, CA, USA
The macromolecular contrast media (MMCM) albumin-(Gd-DTPA) 27 was compared to the small molecular contrast media (SMCM) Gd-DTPA for their suitability to monitor early anti-angiogenic effect of bevacizumab on human breast cancer xenografts in dynamic MRI assays of endothelial permeability in a tandem experiment. Rats were imaged at baseline and 24h after intraperitoneal bevacizumab application. MRI assays of tumor endothelial permeability revealed a significant decrease of endothelial permeability using albumin-(Gd-DTPA) 27 whereas no significant effect was detected using Gd-DTPA. The MMCM albumin-(Gd-DTPA) 27 proved to be superior to the SMCM Gd-DTPA for the detection of early anti-angiogenic effect of bevacizumab.